Viking Therapeutics (VKTX) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$1.55
- Estimate
- -$1.07
- Surprise
- -44.8%
- Score today
- 4.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Viking Therapeutics (VKTX) reported a wider loss than forecast — adjusted EPS of -$1.55 against the -$1.07 estimate (a 44.8% shortfall).
Coverage in the report window
- Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $118 — benzinga, 2026-10-30
- Viking Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Trial Progress — fiscal.ai, 2026-10-30
- CORRECTION: Viking Therapeutics Ticker Is "VKTX" Not "VIK" — benzinga, 2026-10-29
Where TrendMatrix's rating stands now
TrendMatrix currently rates VKTX Sell at 4.7/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -44.8% surprise compares with a -35.2% four-quarter average. Next scheduled report: 2027-02-10.
What argues against it
- Concentration risk — Supplier: CordenPharma
- Concentration risk — Counterparty: Ligand Pharmaceuticals
- DATA_ISSUE: analyst_target_implausible (raw $95.32 vs price $26.66 — ratio 3.6×). Rejected, falling back to technical TP.
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $26.66
- Price target
- $29.50
- Stop
- $24.79
- Upside to target
- +10.7%
Model outputs from TrendMatrix’s engine as of 2026-11-18 — shown for context, not personalized investment advice.
VKTX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.43B
- P/E (fwd)
- -5.2
- 52-week range
- $23.82–$43.10
- Off 52-week high
- 38.2%
- RSI (14)
- 49
- Volume vs avg
- 0.44×
- Score today
- 4.7/10